AXL and non-small cell lung carcinoma: BGB324 (formerly known as R428) is a first-in-class, highly selective small-molecule AXL inhibitor that is currently in Phase I clinical trials to assess its clinical responses in patients with acute myeloid lymphoma and non-small cell lung cancer (NSCLC) [3, 21].